Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program





Faculty/Professorship: Clinical Psychology and Psychotherapy  
Author(s): Kulzer, Bernhard ; Daenschel, Wilfried; Daenschel, Ingrid; Schramm, Wendelin; Messinger, Diethelm; Weißmann, Jörg; Vesper, Iris; Parkin, Christopher G.; Heinemann, Lutz
By: ... ; Weissmann, Joerg; ...
Title of the Journal: Diabetes research and clinical practice : the official journal of the International Diabetes Federation
ISSN: 0168-8227
Publisher Information: Amsterdam [u.a.] : Elsevier
Year of publication: 2018
Issue: 144
Pages: 200-212
Language(s): English
DOI: 10.1016/j.diabres.2018.09.002
URL: https://www.diabetesresearchclinicalpractice.co...
Abstract: 
Aims: Globally, many patients with insulin-treated type-2 diabetes are suboptimally controlled. The PDM-ProValue study program evaluated whether integrated personalized diabetes management (iPDM) has the potential to improve clinical outcomes.
Methods: 101 practices with 907 patients participated in the 12-month, prospective, controlled, cluster-randomized study program. HbA1c levels, therapy changes, frequency of hypoglycemic episodes, patient reported outcomes, and physician satisfaction were assessed.
Results: iPDM led to a greater reduction in HbA1c after 12 months vs. usual care (−0.5%, p < 0.0001 vs. −0.3%, p < 0.0001), (Diff. 0.2%, p = 0.0324). Most of the HbA1c reduction occurred after 3 months and remained stable thereafter. The percentage of patients with therapy adjustments was higher in the iPDM group at all visits (p < 0.01 at week 3, month 3, month 6). Patient adherence at month 12 was higher in the iPDM group compared to baseline (Odds ratio = 2.39; p = 0.0003); also, patient treatment satisfaction (DTSQc: 12.2 vs. 10.4, δ = 1.78, p = 0.004; DTSQs: 31.0 vs. 30.0, δ = 0.924, p = 0.02), and physician satisfaction was higher in the intervention group.
Conclusions: iPDM improved the use of diagnostic data leading to better glycemic control, more timely treatment adjustments (indicating reduced clinical inertia), and increased patient adherence and treatment satisfaction among patients and physicians.
Keywords: Diabetes management, SMBG, Type 2 diabetes, Personalized diabetes therapy, Digital tools
Peer Reviewed: Ja
International Distribution: Ja
Type: Article
URI: https://fis.uni-bamberg.de/handle/uniba/46217
Year of publication: 21. August 2019